AVENUE THERAPEUTICS, INC. (ATXI) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16
	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues	0.0	0.0	0.0	-1.0	0.0	0.0	0.0
Revenue growth			-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	-1.0	0.0	0.0	0.0
Gross margin				100.0%
Selling, general and administrative [+]	5.3	2.5	2.3	3.1	4.1	3.6	1.0
General and administrative	5.3	2.5	2.3	3.1	4.1	3.6	1.0
Research and development	2.7	1.3	2.9	22.2	17.7	6.7	1.3
EBIT [+]	-8.0	-3.7	-5.2	-26.3	-21.8	-10.3	-2.3
EBIT growth	115.2%	-28.3%	-80.2%	20.4%	111.4%	343.2%
EBIT margin				2626.5%
Non-recurring items [+]						1.1	0.0
In-process research & development						1.1	0.0
Interest expense, net [+]	0.0	0.0	-0.1	-0.4	-0.1	0.3	0.6
Interest expense						0.4	0.6
Interest income	0.0	0.0	0.1	0.4	0.1	0.1
Other income (expense), net [+]	4.4				0.2	-0.6	-0.2
Change in fair value of warrants	-5.6					0.5	0.2
Other					-0.2
Pre-tax income	-3.6	-3.7	-5.2	-25.9	-21.5	-12.3	-3.2
Income taxes	-0.1	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	1.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Minority interest	-0.1
Net income	-3.6	-3.7	-5.2	-25.9	-21.5	-12.3	-3.2
Net margin				2590.8%

Basic EPS [+]	($1.63)	($3.29)	($0.31)	($1.65)	($2.10)	($1.85)	($1.11)
Growth	-50.6%	955.1%	-81.1%	-21.7%	13.9%	66.3%
Diluted EPS [+]	($1.63)	($3.29)	($0.31)	($1.65)	($2.10)	($1.85)	($1.11)
Growth	-50.6%	955.1%	-81.1%	-21.7%	13.9%	66.3%

Shares outstanding (basic) [+]	2.2	1.1	16.5	15.7	10.2	6.6	2.9
Growth	92.8%	-93.1%	5.0%	53.5%	54.3%	131.9%
Shares outstanding (diluted) [+]	2.2	1.1	16.5	15.7	10.2	6.6	2.9
Growth	92.8%	-93.1%	5.0%	53.5%	54.3%	131.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.